Website swissbiotech.org

Cenix BioScience and Debiopharm Group™ collaborate to identify predictive biomarkers

Cenix BioScience, a leading preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that they have signed a research agreement to support Debiopharm in its ongoing efforts to develop novel therapeutic drug candidates.

Österreich: AOP von Elan gekauft

Feu vert pour Campus Biotech! L'ancien siège de Serono à Sécheron (Genève).

Transcure Biosciences wins venture kick award of CHF130‘000